MARIA DE FATIMA SILVA MIYAMOTO
Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
bookPart Recomendações de eletrólitos, vitaminas e oligoelementos por via intravenosa(2022) MARIN, Márcia Lucia de Mario; MALUVAYSHI, Cleide Harue; MIYAMOTO, Maria de Fatima Silva; SOUZA, Verônica Chaves de; PINTO, Marina Rossi de Camargo; GOMES, Lidiane BaltieribookPart Avaliação farmacêutica das prescrições de nutrição parenteral (NP)(2022) MARIN, Márcia Lucia de Mario; MALUVAYSHI, Cleide Harue; MIYAMOTO, Maria de Fatima Silva; SOUZA, Verônica Chaves de; PINTO, Marina Rossi de Camargo; GOMES, Lidiane BaltiericonferenceObject Catheter Related Infection in Patients with Intestinal Failure Using Home Parenteral Nutrition(2021) GALVAO, F.; LEE, A.; SCAVIA, T.; ROCHA, M.; CRUZ, M. da; MIYAMOTO, M.; WAISBERG, D.; CARNEIRO-D'ALBUQUERQUE, L.conferenceObject Catheter Related Infection in Patients with Intestinal Failure Using Home Parenteral Nutrition(2021) GALVAO, F.; LEE, A.; SCAVIA, T.; ROCHA, M.; CRUZ, M. da; MIYAMOTO, M.; WAISBERG, D.; CARNEIRO-D'ALBUQUERQUE, L.bookPart Solicitação, recebimento, armazenamento, distribuição e rastreabilidade da nutrição parenteral (manipulada e industrializada)(2022) MARIN, Márcia Lucia de Mario; MALUVAYSHI, Cleide Harue; MIYAMOTO, Maria de Fatima Silva; SOUZA, Verônica Chaves de; PINTO, Marina Rossi de Camargo; GOMES, Lidiane BaltieribookPart Não conformidades na prescrição, preparação, distribuição e administração da terapia de nutrição parenteral (TNP)(2022) MARIN, Márcia Lucia de Mario; MALUVAYSHI, Cleide Harue; MIYAMOTO, Maria de Fatima Silva; SOUZA, Verônica Chaves de; PINTO, Marina Rossi de Camargo; GOMES, Lidiane BaltiericonferenceObject Catheter-Related Infection Rate in Patients in Home Parenteral Nutrition: AMULSIC Group results from 2014 to 2016(2017) RANA, Tatiana Da Cunha; LEE, Andre; SCAVIA, Thanya Alejandra Saxton; ROCHA, Mariana Hollanda Martins Da; CRUZ, Marcia Lucas Fernandes Da; MIYAMOTO, Maria De Fatima Silva; WAISBERG, Daniel; GALVAO, Flavio Henrique Ferreira; CRUZ, Maria Emilia Lucas Fernandes DabookPart Compatibilidade e estabilidade na nutrição parenteral (NP)(2022) MARIN, Márcia Lucia de Mario; MALUVAYSHI, Cleide Harue; MIYAMOTO, Maria de Fatima Silva; SOUZA, Verônica Chaves de; PINTO, Marina Rossi de Camargo; GOMES, Lidiane Baltieri- Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19)(2021) ALENCAR, Julio Cesar Garcia de; MOREIRA, Claudia de Lucena; MULLER, Alicia Dudy; CHAVES, Cleuber Esteves; FUKUHARA, Marina Akemi; SILVA, Elizabeth Aparecida da; MIYAMOTO, Maria de Fatima Silva; PINTO, Vanusa Barbosa; BUENO, Caue Gasparotto; LAZAR NETO, Felippe; GOMEZ, Luz Marina Gomez; MENEZES, Maria Clara Saad; MARCHINI, Julio Flavio Meirelles; MARINO, Lucas Oliveira; BRANDAO NETO, Rodrigo Antonio; SOUZA, Heraldo PossoloBackground: A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce a redox imbalance in alveolar epithelium cells, causing apoptosis, increased inflammation and, consequently, impaired gas exchange. We hypothesized that N-acetylcysteine (NAC) administration could restore this redox homeostasis and suppress unfavorable evolution in patients with coronavirus disease 2019 (COVID-19). Methods: This was a double-blind, randomized, placebo-controlled, single-center trial conducted at the Emergency Department of Hospital das Clinicas, Sao Paulo, Brazil, to determine whether NAC in high doses can avoid respiratory failure in patients with COVID-19. We enrolled 135 patients with severe COVID-19 (confirmed or suspected), with an oxyhemoglobin saturation <94% or respiratory rate >24 breaths/minute. Patients were randomized to receive NAC 21 g (similar to 300 mg/kg) for 20 hours or dextrose 5%. The primary endpoint was the need for mechanical ventilation. Secondary endpoints were time of mechanical ventilation, admission to the intensive care unit (ICU), time in ICU, and mortality. Results: Baseline characteristics were similar between the 2 groups, with no significant differences in age, sex, comorbidities, medicines taken, and disease severity. Also, groups were similar in laboratory tests and chest computed tomography scan findings. Sixteen patients (23.9%) in the placebo group received endotracheal intubation and mechanical ventilation, compared with 14 patients (20.6%) in the NAC group (P = .675). No difference was observed in secondary endpoints. Conclusions: Administration of NAC in high doses did not affect the evolution of severe COVID-19.